Mounjaro approved to reduce cardiovascular events in adults with diabetes

The FDA has approved tirzepatide for reduction of cardiovascular risk in adults with type 2 diabetes, Eli Lilly announced.Tirzepatide (Mounjaro), a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, was already approved for improvement of glucose levels in patients with diabetes aged at least 10 years, and now has an indication for lowering risk for major adverse CV

Raccontata dahealio.commorningstar.comendpoints.newsqz.comindependent.co.uktime.com